Nucleic acid therapeutics could be used to target CF disease pathogenesis at its root cause by exogenously supplying the wild-type transcript to enable expression of fully functional CFTR or modifying the genome or transcriptome. The gene discussed is CFTR; the disease is cystic fibrosis.